Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Sheba Medical Center Offers CAR T-Cell Therapy to Patients with Acute Myelogenous Leukemia (AML)

CAR-T Cell Therapy for AML Patients Has Been Developed at Sheba
Since 2016, cutting-edge CAR T-cell therapy in Israel has been provided at Sheba as a treatment for leukemia (ALL) and lymphoma (NHL). Now, the Tel HaShomer hospital offers CAR T-cell therapy for patients with multiple myeloma. As part of a clinical trial, Sheba is also the first medical facility worldwide to pioneer the use of CAR T-cell therapy to treat acute myelogenous leukemia (AML) with 8;21 translocation and CD19 expression. Cancer patients who had exhausted all lines of treatment face a promising new option.

CAR T-cell therapy is a revolutionary, individualized immune cell therapy used to treat cancer. To administer this state-of-the-art treatment at Sheba Medical Center, a doctor first extracts blood from the patient and sends it to the on-site Oncology Training Laboratories. Presently, Sheba is the only center in Israel that has a lab for preparing and engineering CAR T-cells.

At this highly specialized lab, the T-cells, a type of immune cell, are separated from the rest of the blood cells and genetically engineered to produce CARs (chimeric antigen receptors). The modified T-cells are given time to multiply in the laboratory until there is a sufficient amount to inject back into the patient. Now though, as a result of the CARs, the T-cells behave differently – they are programmed with the ability to identify, target, and destroy tumor cells.

While the T-cells reproduce in Sheba’s laboratory, chemotherapy is delivered to the patient to suppress their immune system. This is done to help maximize the efficiency of the modified T-cells once they are injected into the patient. Altogether, the CAR T-cell therapy process takes approximately 10 days, and patients generally remain hospitalized for about two weeks for observation.

The first child with leukemia to be treated with CAR T-cell therapy in Israel achieved total remission. Since then, the success rates for achieving remission have been 85% in young children, approximately 80% in teenagers.

In October 2019, a ceremony was held to mark 130 patients treated with CAR T-cell therapy at Sheba Medical Center. In the words of Prof. Yitzhak Kreiss, Director of Sheba Medical Center, “[This] ceremony represents a transition from vision to courage – the creation of a world where CAR T-cell therapy becomes a standard part of the institutional care we offer to patients. This treatment is a connection between science and research, between laboratory capabilities and regulation, and most importantly – between all of the above and the patient. That’s our wonderful story – a tale of partnership and progress.”

Now, Sheba is excited to promote the availability of CAR T-cell therapy for patients with multiple myeloma. Additionally, patients with acute myelogenous leukemia (AML) with 8;21 translocation and CD19 expression, can receive the immune cell therapy as part of a clinical trial at Sheba. Sheba is the first and currently the only medical center in the world to offer CAR T-cell therapy for AML.

arnon nagler
Prof. Arnon Nagler

Prof. Arnon Nagler, Director of Hematology, announces, “The ground-breaking CAR T-cell treatment that was applied at Sheba for over 130 patients suffering from ALL or NHL, is now approved for use in patients with multiple myeloma as part of a clinical trial. Moreover, Sheba is the first medical center in the world to pioneer CAR T-cell therapy application for AML patients with 8;21 translocation and CD19 expression. Patients interested in undergoing this innovative treatment at Sheba will be offered a full diagnostic procedure to determine whether this treatment is a suitable option for them.”

Sheba's Legacy of Hope: Alexandra's Remarkable Road to Wellness
Last month, a celebratory atmosphere filled the halls of the Edmond and Lily Safra Children’s Hospital at Sheba. The occasion marked a significant milestone in…
Read More
Kerry's Fight Against Skin Cancer at Sheba
Looking back at 2020, 55-year-old Kerry Louise Matthews was in love with her life. Despite the pandemic, the UK native had just started on a…
Read More
Sheba Ranked Among the Top 10 Hospitals in the World by Newsweek
We are pleased to announce that for the sixth consecutive year, Sheba has been recognized as one of the best hospitals in the world by…
Read More